Cassava Alzheimer's candidate simufilam clears phase 3 safety review

seekingalpha03-25

A Data and Safety Monitoring Board has recommended that Cassava Sciences (NASDAQ:SAVA) continue its phase 3 program for its Alzheimer's candidate simufilam. CEO Remi Barbier noted that top-line ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2422547730?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg","is_english":true,"pubTime":"2024-03-25 23:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422547730","market":"hk","top_or_hot":-1,"title":"Cassava Alzheimer's candidate simufilam clears phase 3 safety review","media":"seekingalpha","content":"<div>\n<p>A Data and Safety Monitoring Board has recommended that Cassava Sciences (NASDAQ:SAVA) continue its phase 3 program for its Alzheimer's candidate simufilam.\nCEO Remi Barbier noted that top-line ...</p>\n\n<a href=\"https://seekingalpha.com/news/4083350-cassava-alzheimers-candidate-simufilam-clears-phase-3-safety-review\">Source Link</a>\n\n</div>\n","source":"seekingalpha_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Alzheimer's candidate simufilam clears phase 3 safety review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Alzheimer's candidate simufilam clears phase 3 safety review\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-25 23:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4083350-cassava-alzheimers-candidate-simufilam-clears-phase-3-safety-review><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A Data and Safety Monitoring Board has recommended that Cassava Sciences (NASDAQ:SAVA) continue its phase 3 program for its Alzheimer's candidate simufilam.\nCEO Remi Barbier noted that top-line ...</p>\n\n<a href=\"https://seekingalpha.com/news/4083350-cassava-alzheimers-candidate-simufilam-clears-phase-3-safety-review\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4083350-cassava-alzheimers-candidate-simufilam-clears-phase-3-safety-review","article_id":"2422547730","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422547730","pubTimestamp":1711382336,"sourceInfo":{"source_id":"seekingalpha_hot_news","name":"SeekingAlpha"},"weMediaInfo":null,"summary":"AData and Safety Monitoring Board has recommended that Cassava Sciences  continue its phase 3 program for its Alzheimer's candidate simufilam.CEO Remi Barbier noted thattop-line efficacy data for the 12-month study is due later this year.The board is only charged with reviewing safety, not efficacy.More on Cassava Sciences  Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go?Cassava Sciences And Alzheimer's Disease: Opaque Clarity Biotech And Pharma Diversification Pays Off Cassava Sciences again under scrutiny over Alzheimer's drug research Seeking Alpha’s Quant Rating on Cassava Sciences","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc","BK4547":"WSB热门概念","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4007":"制药"},"translate_title":"木薯阿尔茨海默病候选药物simufilam通过3期安全性审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":1},"content_text":"A Data and Safety Monitoring Board has recommended that Cassava Sciences (NASDAQ:SAVA) continue its phase 3 program for its Alzheimer's candidate simufilam.\nCEO Remi Barbier noted that top-line efficacy data for the 12-month study is due later this year.\nThe board is only charged with reviewing safety, not efficacy.\n\n\nMore on Cassava Sciences  Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go? Cassava Sciences And Alzheimer's Disease: Opaque Clarity Biotech And Pharma Diversification Pays Off Cassava Sciences again under scrutiny over Alzheimer's drug research Seeking Alpha’s Quant Rating on Cassava Sciences","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422547730"}